Calculating plaque-forming units per milliliter comes down to a short formula: divide the average number of plaques you count at a given dilution by the product of that dilution factor and the volume of virus you added to the well. The formula is PFU/mL = average plaque count ÷ (dilution factor × inoculum volume in mL). A protocol for SARS-CoV-2 quantification, for instance, specifies exactly this: take the average number of plaques at the dilution yielding countable results and divide by the dilution factor multiplied by the 0.1 mL inoculum volume.1PubMed Central. Two Detailed Plaque Assay Protocols for the Quantification of Infectious SARS‐CoV‐2 The formula itself is simple, but every step feeding into it, from serial dilution to plaque counting, introduces decisions that affect your final number.
What a Plaque Assay Actually Measures
A plaque assay measures the concentration of infectious virus particles in a sample. That word “infectious” is key. Unlike molecular methods that detect genetic material regardless of whether a virus can still replicate, the plaque assay only counts viruses that are capable of infecting a cell, reproducing inside it, and killing enough neighboring cells to create a visible hole in the cell layer. The assay remains the gold standard for quantifying replication-competent lytic virions.1PubMed Central. Two Detailed Plaque Assay Protocols for the Quantification of Infectious SARS‐CoV‐2
The setup involves growing a single layer of susceptible cells in a dish, adding a known volume of diluted virus, and then covering everything with a semisolid overlay, typically agarose or carboxymethyl cellulose. That overlay prevents the virus from drifting freely through liquid and infecting distant cells. Instead, each infectious particle can only spread to its immediate neighbors, producing a localized zone of dead cells called a plaque.2PubMed Central. Viral Concentration Determination Through Plaque Assays: Using Traditional and Novel Overlay Systems Each plaque, in theory, traces back to one infectious unit. Count the plaques, account for how much you diluted the sample, and you have a titer in PFU/mL.
Setting Up Serial Dilutions
You rarely add undiluted virus to a plate. An undiluted stock might contain millions or billions of infectious particles per milliliter, and if all of them hit the cell layer at once, the entire monolayer would be destroyed with no individual plaques to count. Serial dilution solves this by progressively reducing the virus concentration in controlled steps.
A standard approach uses tenfold dilutions. You transfer 100 µL of sample into 900 µL of medium, mix thoroughly, then take 100 µL from that tube into the next 900 µL, and so on. Each step reduces the virus concentration by a factor of ten. A typical series runs from 10⁻¹ through 10⁻⁶ or beyond.1PubMed Central. Two Detailed Plaque Assay Protocols for the Quantification of Infectious SARS‐CoV‐2 Different dilutions are then added to separate wells or plates so that at least one dilution lands in the sweet spot for counting.
The mixing step between each transfer matters more than people expect. If you do not vortex or pipette-mix properly, the concentration carried forward is unpredictable, and your final titer will be off. Dilution and pipetting errors are, in fact, the most common sources of error in the entire assay.3Microbiology of Waterborne Diseases. DESTRUCTION OF VIRUSES
Walking Through the Calculation
Once plaques have developed (usually over a few days, depending on the virus), you pick the dilution that gives you a countable number of plaques per well. A commonly cited target range is about 5 to 100 plaques per well.1PubMed Central. Two Detailed Plaque Assay Protocols for the Quantification of Infectious SARS‐CoV‐2 Too few plaques and random variation dominates. Too many and the plaques start merging into one another, making individual counts unreliable.
Suppose you ran duplicates at the 10⁻⁷ dilution, counted 30 plaques in one well and 32 in the other, and you had added 0.4 mL of diluted virus to each well. First, average the counts: (30 + 32) ÷ 2 = 31. Then plug into the formula: 31 ÷ (10⁻⁷ × 0.4 mL) = 7.75 × 10⁸ PFU/mL.2PubMed Central. Viral Concentration Determination Through Plaque Assays: Using Traditional and Novel Overlay Systems That result tells you the original undiluted stock contains roughly 775 million infectious particles per milliliter.
A few things to watch. First, always use duplicates or triplicates at each dilution and average the counts. A single well is not reliable on its own. Second, the inoculum volume must match what you actually added, not a default assumption. If your protocol calls for 0.1 mL per well, use 0.1 in the formula. If it calls for 0.4 mL, use 0.4. Getting this wrong scales your titer by a factor of four in this example, which is a huge error for downstream work.
Making Plaques Visible
A plaque is technically just a patch of dead or lysed cells in an otherwise healthy monolayer, but telling the difference between healthy cells and empty space is not always obvious to the naked eye. That is where staining comes in. The two broad strategies are vital dyes, which stain living cells and leave plaques as clear spots, and fixation dyes, which stain everything that remains after the overlay is removed.
Neutral red is the most common vital dye. It is taken up only by living cells, so healthy areas turn pink while plaques stay colorless.4Microbiology of Waterborne Diseases. Methods for the Detection of Waterborne Viruses In one murine norovirus protocol, cells are stained with a 0.01% neutral red solution in PBS for one to three hours before the solution is aspirated and plaques are counted.5PubMed Central. Neutral Red Assay for Murine Norovirus Replication and Detection in a Mouse Crystal violet, methylene blue, and Giemsa are fixation-based alternatives; they stain the remaining live cells after the overlay is removed, again leaving plaques as unstained holes.
The choice of stain can actually affect whether you see plaques at all. Work with human coronaviruses demonstrated that on one cell line, plaques were visible with either neutral red or crystal violet, but on another cell line, only neutral red staining revealed them, because the virus killed cells without causing the kind of visible structural changes that fixation stains rely on.6PubMed Central. Plaque assay and improved yield of human coronaviruses in a human rhabdomyosarcoma cell line If you are not seeing plaques you expect, switching stains is worth trying before concluding that the virus is not there.
Where the Numbers Go Wrong
The formula is straightforward, but the assay feeding it is sensitive to a long list of variables. Cell type, cell density, culture medium, the age of the monolayer, the virus strain used, and the skill of the person running the assay all affect reproducibility. For herpes simplex virus, well-controlled assays can keep variation within 0.3 log₁₀ (roughly a factor of two), but sloppier technique pushes variability much higher.3Microbiology of Waterborne Diseases. DESTRUCTION OF VIRUSES
Some common pitfalls beyond dilution errors:
- Overlapping plaques: When too many infectious particles land in a small area, their plaques merge and become impossible to distinguish. This is why you need multiple dilutions and why counting should focus on wells with fewer than about 100 discrete plaques.
- Uneven cell layers: If the monolayer has gaps or uneven thickness, those areas can mimic plaques or mask real ones.
- Overlay problems: If the overlay is too warm when poured, it kills cells on contact. If it is too thin or too fluid, virus drifts through it, producing diffuse or irregular plaques.
- Timing: Reading plates too early misses slow-forming plaques; reading too late lets plaques expand and merge.
Because the plaque count reflects only viruses that successfully infected, replicated, and killed cells under those exact conditions, the result is always a minimum estimate of how many infectious particles were present. Particles that landed on an already-dead cell, failed to attach, or got trapped in the overlay will not produce plaques.
Automated Counting and How It Compares
Manual plaque counting is tedious and introduces subjectivity. Two trained analysts looking at the same well may disagree on borderline plaques or faint clearings. Software tools have been developed to reduce this variability and speed up the process.
One widely tested tool, Viridot, showed a concordance correlation of 0.99 with manual counts, meaning automated and manual results were essentially interchangeable.7PLoS Neglected Tropical Diseases. Viridot: An automated virus plaque (immunofocus) counter for the measurement of serological neutralizing responses with application to dengue virus Another tool, ViralPlaque, cut processing time by three- to fivefold compared to manual measurement while maintaining strong correlation with hand counts.8PubMed Central. ViralPlaque: a Fiji macro for automated assessment of viral plaque statistics A program called plaQuest, tested with chikungunya virus, produced counts statistically indistinguishable from manual results, though it tended to slightly undercount because of a border exclusion zone around the edges of each well.9Scientific Reports. Development of an automated plaque-counting program for the quantification of the Chikungunya virus
In practice, automated tools work best when plaques have high contrast against the background. Faintly stained or irregularly shaped plaques still challenge software, and most protocols recommend a quick manual review of flagged images. But for high-throughput work where you are processing dozens or hundreds of plates, automation is a practical necessity.
How PFU Relates to Other Ways of Measuring Virus
PFU/mL is not the only metric you will encounter. Other common measures include TCID₅₀ (the dilution at which half of replicate cell cultures become infected), genome copies per milliliter (from PCR), and total particle counts (from electron microscopy or nanoparticle tracking). These numbers can differ from PFU by orders of magnitude, and understanding why keeps you from misinterpreting results.
The most direct comparison is between PFU and TCID₅₀. Both measure infectious virus, but they use different endpoints (visible plaques vs. any cytopathic effect in a well). A commonly used conversion factor is 0.56, meaning one TCID₅₀ unit corresponds to roughly 0.56 PFU.10PubMed Central. Comparison among plaque assay, tissue culture infectious dose (TCID 50 ) and real-time RT-PCR for SARS-CoV-2 variants quantification This is a theoretical relationship derived from Poisson statistics and the assumption that one infectious unit is sufficient to produce a plaque. In reality, the ratio varies by virus and cell line, so relying on a universal conversion factor introduces some imprecision.
Genome copies measured by PCR typically outnumber PFU dramatically. For yellow fever virus, the ratio of genomes to infectious particles was estimated at somewhere between 1,000:1 and 5,000:1, though the two measurements were well correlated.11PubMed. Detection of yellow fever virus: a comparison of quantitative real-time PCR and plaque assay For respiratory syncytial virus, genome copy number of one particular gene was highly correlated with plaque-forming units, making PCR a useful proxy when plaque assays are impractical.12PubMed. Evaluation of consistency in quantification of gene copy number by real-time reverse transcription quantitative polymerase chain reaction and virus titer by plaque-forming assay for human respiratory syncytial virus For Tulane virus, one PFU corresponded to roughly 10 untreated genome copies and about 3 RNase-treated copies.13PubMed. Comparison of cell-based and PCR-based assays as methods for measuring infectivity of Tulane virus
Total particle counts diverge even further. Ebola virus stocks grown in Vero E6 cells contained particle concentrations roughly 10,000-fold higher than their PFU titers, meaning only about one in every ten thousand particles produced a plaque.14PubMed Central. Particle-to-PFU Ratio of Ebola Virus Influences Disease Course and Survival in Cynomolgus Macaques This gap exists because many particles are physically damaged, genetically defective, or simply land in unfavorable positions during the assay. The particle-to-PFU ratio is not just a measurement artifact; in that Ebola study, it influenced disease progression and survival in animal models, making it a biologically meaningful variable rather than just a technical curiosity.
When Plaques Do Not Form
Not every virus kills cells in a way that creates clear plaques. Some viruses replicate inside cells without destroying them. Others cause such subtle damage that it does not show up as a visible hole, even with staining. For these viruses, the standard plaque assay either fails outright or dramatically underestimates the titer.
The focus-forming assay is the workaround. Instead of waiting for cells to die and leave a visible gap, you use antibodies tagged with a fluorescent or colored marker to detect viral proteins in infected cells. The result is a cluster of stained infected cells called a focus, and the titer is expressed as focus-forming units (FFU) per milliliter. The math is identical to the PFU calculation: average the focus count at a countable dilution and divide by the dilution factor times the inoculum volume. An infrared fluorescent version of this assay was validated for hepatitis A virus and measles virus, both of which are difficult to quantify by conventional plaque methods, and showed a linear relationship between virus dilution and focus count.15PubMed. Infrared fluorescent immunofocus assay (IR-FIFA) for the quantitation of non-cytopathic and minimally cytopathic viruses
PFU in Neutralization Testing
Plaque counts are not only used to measure how much virus is in a stock. They also form the backbone of the plaque reduction neutralization test (PRNT), which measures how effectively antibodies in a blood sample can block viral infection. This is the standard method for evaluating vaccine-induced immunity against flaviviruses like dengue.
In a PRNT, you mix a known quantity of virus with serial dilutions of the serum you want to test. The mixture is then added to cells and overlaid as in a standard plaque assay. The serum dilution at which plaque counts drop by 50% compared to a virus-only control is the PRNT₅₀ titer. It is calculated using a four-point regression of the plaque counts across dilutions.16PubMed Central. Optimization and Validation of a Plaque Reduction Neutralization Test for the Detection of Neutralizing Antibodies to Four Serotypes of Dengue Virus Used in Support of Dengue Vaccine Development Because PFU directly quantifies infectious virus, a reduction in plaque count provides a functional measure of how well antibodies are actually preventing infection, not just binding to the virus.
The accuracy of the PRNT depends heavily on the precision of the underlying plaque assay. If your baseline plaque count in the virus-only control wells is unreliable, the 50% reduction threshold becomes meaningless. Consistent technique, adequate replication, and careful dilution matter even more here than in a simple titer determination, because you are comparing counts across conditions rather than simply reporting an absolute number.
Statistical Assumptions Behind the Count
The entire PFU framework rests on the assumption that each plaque represents exactly one infectious event, meaning the distribution of infectious particles across a plate follows a Poisson process: events are random, independent, and occur at a constant average rate. For most practical purposes this holds well enough, but it starts to break down at extremes. At very low counts, random variation dominates, and a difference of two or three plaques translates into large percentage swings in the calculated titer. At very high counts, plaques overlap and the assumption of independence falls apart.
Researchers studying viral clearance in biological products have proposed Poisson-based statistical methods that outperform simple averaging, particularly when counts are very low or when post-processing counts drop to zero.17Elsevier / Biologicals. Statistical evaluations of viral clearance studies for biological products These methods also provide exact confidence intervals for the titer estimate, which simple averaging does not. For routine laboratory work, averaging replicates at a well-populated dilution is perfectly adequate. But for regulatory submissions or any context where the lower limit of detection matters, Poisson-based methods give you more defensible numbers.
Multiplicity of Infection and Why Your Titer Matters Downstream
Once you have a PFU/mL value, one of its most common uses is calculating the multiplicity of infection (MOI), which is the ratio of infectious particles to target cells. If you have 10⁷ PFU/mL in your stock and you want to infect one million cells at an MOI of 1, you need to add 10⁶ PFU, which in this case would be 0.1 mL of stock. Getting the MOI right is critical in experiments studying viral replication kinetics, gene expression, or therapeutic applications like phage therapy.
Research optimizing bacteriophage MOI for controlling drug-resistant E. coli found that the effective MOI varied enormously across different bacterial strains, from about 4 to more than 800, depending on the target.18PubMed Central. A revisited two-step microtiter plate assay: Optimization of in vitro multiplicity of infection (MOI) for Coliphage and Vibriophage An inaccurate PFU determination would cascade through every MOI calculation, leading you to under- or over-infect your cultures and potentially misinterpret results. The plaque assay may be a century-old technique, tracing back to bacteriophage work that was adapted to animal viruses in the 1950s, but getting it right still anchors a surprising amount of modern virology.19PubMed. From plaques to pocks: carrying over bacteriophage assay techniques to the study of influenza and other animal viruses